Risk of Arterial and Venous Thrombosis in G20210A Heterozygous Mutation

Venous Thrombosis Risk

The prothrombin G20210A mutation is the second most common heritable risk factor for VTE, present in approximately 6% of individuals with an initial episode of venous thrombosis 1
Heterozygosity for the G20210A mutation occurs in approximately 2.2% of non-Hispanic whites, 2.2% of Hispanic whites, and 0.6% of African Americans in the United States 1
Population studies indicate that heterozygosity for the G20210A mutation increases the risk of an initial VTE episode by 2-4 fold compared to the general population 1, 2

The association between G20210A heterozygosity and arterial thrombotic events remains controversial 3
Meta-analyses have found modest associations between the G20210A mutation and arterial thrombotic events (OR, 1.32; 95% CI, 1.03 to 1.69), with stronger associations in younger patients (<55 years of age) 3

Compound heterozygosity (G20210A plus Factor V Leiden) is associated with a 20-fold increased risk for initial VTE episodes 1, 2

Testing for the G20210A mutation is recommended for patients under age 50 with any venous thrombosis, patients with venous thrombosis in unusual sites, and those with recurrent venous thrombosis 4
For patients with a first VTE and heterozygous G20210A mutation without other risk factors, anticoagulation for 3 months is generally recommended for provoked events, while unprovoked events require at least 3 months with consideration for extended therapy 5
Patients with G20210A heterozygosity alone (without other thrombophilic conditions or recurrent events) do not routinely require long-term anticoagulation 5
Knowledge of G20210A status in asymptomatic relatives can guide antithrombotic prophylaxis during high-risk periods, such as surgery or postpartum periods 5, 4

The prothrombin G20210A mutation is recognized as a primary risk factor for venous thromboembolism (VTE), including pulmonary embolism, by the European Society of Cardiology 6, 7
Advanced age is listed as a secondary risk factor for VTE that often acts independently or synergistically with genetic factors, according to the European Heart Journal 6, 7

Most PE cases occur between ages 60-70 in clinical studies, with autopsy series showing peaks between 70-80 years, as reported in the European Heart Journal 6
The association between prothrombin G20210A and thrombotic events is strongest in younger patients (<55 years), with more controversial significance in older populations, as noted in Stroke 8, 9

Almost one in two cases of PE occur without classical predisposing factors, according to the European Heart Journal 6
Age-related comorbidities (cancer, heart failure, immobilization, recent surgery) are often the actual drivers of VTE rather than genetic factors, as stated in the European Heart Journal 6
The mutation's relative contribution diminishes when competing high-risk mechanisms are present, as reported in Stroke 8, 9

The American College of Cardiology recommends considering the prothrombin G20210A mutation as a causative factor if the PE occurred without obvious secondary triggers, there is a history of recurrent VTE, or there is a positive family history of thrombosis 6
The European Society of Cardiology suggests that patients with G20210A heterozygosity alone do not routinely require lifelong anticoagulation, but rather at least 3 months of anticoagulation for provoked events and consideration for extended therapy for unprovoked events 6